Cipla Limited

Cipla Ltd. announced the appointment of two new board members during its 88th Annual General Meeting: Mrs. Maya Hari and Mrs. Sharmila Paranjpe. This change comes as the company bids farewell to five outgoing directors, highlighting a strategic shift in its leadership team.

In FY2024, Cipla Ltd. achieved remarkable financial performance, with total revenue surpassing Rs. 25,000 Crores, reflecting a robust growth rate of 14%. The company also reported a significant profit increase of 47%, alongside an impressive EBITDA growth of 26%. Notably, Cipla's revenue from the Indian market exceeded Rs. 10,000 Crores, while its North American revenue reached $900 million, marking a substantial 24% growth in that region. This strong financial performance underscores Cipla's position as a leading player in the pharmaceutical industry.

Cipla Ltd. is strategically leveraging digitalization and technology to drive future growth and innovation by investing in advanced medical technologies and automation. The company is focusing on areas such as biotech, gene therapy, stem cells, and mRNA technologies, which are essential for developing innovative treatments for unmet medical needs. Additionally, Cipla is enhancing its manufacturing, marketing, and distribution processes through digitalization, aiming to improve operational efficiencies and expand access to quality healthcare. This commitment to integrating cutting-edge technology positions Cipla as a leader in the pharmaceutical industry, ensuring sustainable growth and improved patient outcomes.

Cipla Ltd.'s 88th Annual General Meeting, held on August 20, 2024, showcased significant achievements and strategic initiatives. Key highlights included the company surpassing an annual revenue of Rs. 25,000 Crores, marking a 14% growth rate and a remarkable 47% increase in profit. Cipla reaffirmed its leadership in respiratory medicine and emphasized its market dominance with brands like Foracort and Astelin. The company is also investing in advanced technologies such as biotech, gene therapy, and mRNA technologies to enhance healthcare access. Additionally, Cipla announced the appointment of new board members, Mrs. Maya Hari and Mrs. Sharmila Paranjpe, while bidding farewell to five outgoing directors. The

Cipla Ltd. is actively addressing antimicrobial resistance (AMR) and improving healthcare access through several strategic initiatives. The company is investing in advanced technologies, including biotech, gene therapy, and mRNA technologies, which are crucial for developing innovative treatments. Additionally, Cipla emphasizes its leadership in respiratory medicine and aims to expand access to quality healthcare by focusing on unmet medical needs. By enhancing automation and digitalization in its operations, Cipla is positioning itself to effectively tackle healthcare challenges and contribute significantly to global health improvements.

Cipla Ltd. achieved significant milestones in the past year, solidifying its position in the pharmaceutical industry. The company surpassed an annual revenue of Rs. 25,000 Crores, marking a 14% growth rate and a remarkable 47% increase in profit. Notably, Cipla established itself as a leader in respiratory medicine and maintained market dominance with key brands like Foracort and Astelin. Additionally, the company made strides in expanding its market presence, with Indian revenue exceeding Rs. 10,000 Crores and North American revenue reaching $900 million. Cipla is also investing in innovative technologies such as biotech, gene therapy, and mRNA technologies to enhance healthcare solutions, positioning itself among the leading generic pharma companies globally.